- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01329185
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
Double Blinded Placebo Controlled Study to Assess Clinical and Antiviral Activity of Valganciclovir (VAL) in Solid Organ Transplant Donors to Reduce Viral Transmission From Donor to Recipient
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The potency of new immunosuppressive agents has reduced the risk of the body's immune system rejecting a transplanted kidney. However, this has come with a price. Kidney transplant recipients now face a higher risk of serious infections and related malignancies.
Viral infections are a significant cause of posttransplant morbidity and mortality and two of the herpes viruses have the greatest impact: Epstein-Barr virus (EBV) and Cytomegalovirus (CMV). CMV disease can manifest posttransplant as fever, leukopenia, or mild to severe organ involvement (including pneumonitis, hepatitis, pancreatitis, colitis, meningoencephalitis, and rarely myocarditis). EBV can present posttransplant as infectious mononucleosis syndrome, hepatitis and, in the worse case scenario, a potentially fatal lymphoproliferative disorder called Post-Transplant Lymphoproliferative Disease (PTLD). Moreover, subclinical CMV and/or EBV viremia have been associated with deterioration in kidney function in kidney transplant recipients. Thus, the potential negative impact of these viruses on the lives of transplant recipients is profound and, unfortunately, the complications of these post-transplant viral infections are common and occur despite standard antiviral prophylaxis in the first year posttransplant.
These viral infections, in most instances, originate from the donor organ where these viruses reside in a dormant state, counterbalanced by the donor's healthy immune system. Upon transplantation into the recipient, whose immune system is then severely suppressed by anti-rejection drugs, these viruses become activated, often leading to the above described complications.
The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient. The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the virus to their babies was pivotal to the prevention of AIDS and so along the same lines the investigators will test the hypothesis that 14 days of the anti-viral Valganciclovir (VAL) to kidney donors prior to the transplant compared to placebo will reduce EBV and CMV viremia in the 1st year posttransplant in pediatric kidney recipients. We aim to enroll 20 donor-recipient pairs.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Any person approved as a kidney transplant donor with a recipient who has never undergone a previous transplantation
- Kidney transplant donor must be 18 years old or older
- The kidney transplant donor must be positive for CMV IgG and / or EBV IgG
- The donor must be to a recipient that is discordantly seronegative for the virus for which the donor is seropositive (D+ R-)
- They must have provided signed informed consent
- The potential donors must be willing to contribute samples of blood and oral washings at regular intervals
- The potential donor must state willingness to use effective contraception during treatment and 30 days following receiving the study drug/placebo
- All females must have a negative pregnancy test
- Person must have estimated creatinine clearance (Cockcroft and Gault method) >= 60 ml/min
- Person must have Absolute neutrophil count >= 1000 cells/uL
- Person must have Platelets >= 100,000/uL
- Person must have Hemoglobin >= 9.5 g/dL
Exclusion criteria:
- Any potential kidney transplant donor who is seronegative for both CMV & EBV IgG
- Any potential kidney transplant donor who is receiving or have received anti-herpes medication in the past week
- Any potential kidney transplant donor to a recipient who has received a previous solid organ transplant
- Any potential kidney transplant donor who is immunosuppressed due to medical disease and/or immunosuppressive or immunomodulating medications
- Any potential kidney transplant donor who is breast feeding during the study
- Any potential kidney transplant donor who is on corticosteroids
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Eligible consenting kidney transplant donors who are randomized to receive placebo will be given 1 placebo in morning and 1 in evening for 14 days prior to transplant date
|
1 capsule twice a day for 14 days prior to transplant date
|
Experimental: Valganciclovir
Eligible consenting kidney transplant donors who are randomized to the experimental arm of the study will receive 450mg of Valganciclovir twice a day for 14 days prior to the transplant date
|
Valganciclovir 450mg twice a day for 14 days prior to transplant date
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of EBV or CMV Related Disease in Transplant Recipient
Time Frame: At least 1 year
|
Incidence of EBV or CMV related disease in the transplant recipients of enrolled donors.
|
At least 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Priya Verghese, MD, MPH, University of Minnesota
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1012M93572
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CMV Viremia
-
Hospital Israelita Albert EinsteinRecruiting
-
University of Alabama at BirminghamRecruitingCmv Congenital | CMV ViremiaBrazil
-
Hospital do Rim e HipertensãoEnrolling by invitationCMV Infection | CMV ViremiaBrazil
-
University Medical Centre LjubljanaRecruiting
-
Atara BiotherapeuticsNo longer available
-
Memorial Sloan Kettering Cancer CenterRecruitingCMV Infection | Persistent CMV ViremiaUnited States
-
Peking University People's HospitalRecruitingTransplantation Infection | CMV ViremiaChina
-
University of Wisconsin, MadisonUniversity of Wisconsin Carbone Cancer Center (UWCCC)RecruitingCytomegalovirus Infections | Opportunistic Infections | CMV Infection | CMV ViremiaUnited States
-
Banc de Sang i TeixitsHospital Universitario La Fe; Vall d'Hebron Institute of OncologyCompletedCMV Viremia | Immunosuppression-related Infectious DiseaseSpain
-
Peking University People's HospitalUnknownAcute Leukemia | Hematopoietic Stem Cell Transplantation | CMV ViremiaChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States